Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy
Código 901920 (Harmonized System 2012 by 6 digits)
Código 901920 (Harmonized System 2012 by 6 digits)
United States: US$452M, Main commercial destination (2024)
In 2024, the countries with the most international purchases from Mexico were United States (US$452M), France (US$24.2M), New Zealand (US$9.92M), Germany (US$9.66M), and Canada (US$7.66M).
United States: US$141M, Main Commercial Origin (2024)
The countries with the most international sales to Mexico in 2024 were United States (US$141M), China (US$39.9M), Dominican Republic (US$15.2M), New Zealand (US$13.1M), and Germany (US$12.5M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were China (US$15.5B), United States (US$12.7B), and Singapore (US$10.6B). In the same year, the main importing countries for Ozone Therapy Devices, Oxygen Therapy and Aerosol Therapy, Respiratory Devices and other Equipment Resuscitation Respiratory Therapy were United States (US$25.5B), Netherlands (US$6.39B), and Germany (US$6.12B).